Table 1 Clinical data of breast cancer patients used in this study (n (%))
From: Significance of ERβ expression in different molecular subtypes of breast cancer
Clinical features | Cases (%) | Clinical features | Cases (%) |
|---|---|---|---|
Menses | Staging | ||
Menostasis | 355 (50.1) | Stage 0 | 218 (30.7) |
Non-menostasis | 354 (49.9) | Stage 1 | 339 (47.8) |
Age (years) | Stage 2 | 152 (21.4) | |
≤ 39 | 164 (23.1) | Chemotherapy | |
≥ 40 ~ 59 | 399 (56.3) | Yes | 595 (83.9) |
≥ 60 | 146 (20.6) | No | 114 (16.1) |
Tumor size (cm) | Radiotherapy | ||
≤ 2 | 329 (46.4) | Yes | 454 (64.0) |
> 2 -- ≤ 3 | 380 (53.6) | No | 255 (36.0) |
Lymph node metastasis | Endocrine therapy | ||
L0 | 385 (54.3) | Yes | 290 (40.9) |
L1~4 | 324 (45.7) | No | 419 (59.1) |